Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma-Reference-Cited by-同舟云学术

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

Published:2015-02-23 Issue:4 Volume:125 Page:1459-1470
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Kwong Lawrence N.,Boland Genevieve M.,Frederick Dennie T.,Helms Timothy L.,Akid Ahmad T.,Miller John P.,Jiang Shan,Cooper Zachary A.,Song Xingzhi,Seth Sahil,Kamara Jennifer,Protopopov Alexei,Mills Gordon B.,Flaherty Keith T.,Wargo Jennifer A.,Chin Lynda

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference50 articles.

1. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

2. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

3. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

4. Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma

5. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK;Cell Host & Microbe;2024-08

2. A Gold Standard-Derived Modular Barcoding Approach to Cancer Transcriptomics;Cancers;2024-05-15

3. A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation;Cancer Discovery;2024-05-01

4. Cost and time-efficient construction of a 3′-end mRNA library from unpurified bulk RNA in a single tube;Experimental & Molecular Medicine;2024-02-27

5. Harnessing the potential of reverse‐phase protein array technology: Advancing precision oncology strategies;Cancer Science;2024-02-26